Brain Metastasis Prediction by Transcriptomic Profiling in Triple‐Negative Breast Cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Breast Cancer

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clbc.2016.08.008PMID 27692773
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Supplemental Table 1

  2016cited by this paper
• A comparison between DASL and Affymetrix on probing the whole-transcriptome

  2016cited by this paper
• The role of tau in the pathological process and clinical expression of Huntington’s disease

  2015cited by this paper
• Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

  2015cited by this paper
• Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

  2015cited by this paper
• Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients

  2015cited by this paper
• Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing

  2015cited by this paper
• Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients

  2015cited by this paper
• Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

  2015cited by this paper
• Molecular Heterogeneity of Triple-Negative Breast Cancer

  2014cited by this paper
• Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

  2014cited by this paper
• Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

  2014cited by this paper
• New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity

  2014cited by this paper
• αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain

  2013cited by this paper
• Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Abstract A69: aB-crystallin: A novel regulator of breast cancer metastasis to the brain

  2013cited by this paper
• Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.

  2012cited by this paper
• Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer.

  2012cited by this paper
• Transcriptional Profiling of Formalin Fixed Paraffin Embedded Tissue: Pitfalls and Recommendations for Identifying Biologically Relevant Changes

  2012cited by this paper
• TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer

  2012cited by this paper
• Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

  2012cited by this paper
• Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer

  2012cited by this paper
• Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression

  2012cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011influential reference
• Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

  2011cited by this paper
• Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer.

  2011cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Survival among women with triple receptor-negative breast cancer and brain metastases.

  2009cited by this paper
• Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer

  2009cited by this paper
• Genes that mediate breast cancer metastasis to the brain

  2009cited by this paper
• Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival

  2009cited by this paper
• Chemotherapy-induced tumor gene expression changes in human breast cancers

  2009cited by this paper
• Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer.

  2008cited by this paper
• Survival in patients with brain metastases from breast cancer

  2008cited by this paper
• Optimization of the method of RNA isolation from paraffin blocks to assess gene expression in breast cancer.

  2008cited by this paper
• Breast cancer subtypes and survival in patients with brain metastases

  2008cited by this paper
• Triple-negative breast cancer.

  2008influential reference
• Methylated NEUROD1 Promoter is a Marker for Chemosensitivity in Breast Cancer

  2008cited by this paper
• Analysis of Gene Expression Data Using BRB-Array Tools

  2007cited by this paper
• Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR

  2006cited by this paper
• FTDP-17 Mutations Compromise the Ability of Tau to Regulate Microtubule Dynamics in Cells*

  2006cited by this paper
• Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

  2006cited by this paper
• Microtubule Associated Protein (MAP)-Tau: A Novel Mediator of Paclitaxel Sensitivity In Vitro and In Vivo

  2005cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2005cited by this paper
• Central nervous system metastases in patients with high‐risk breast carcinoma after multimodality treatment

  2004cited by this paper
• Analysis of gene expression involved in brain metastasis from breast cancer using cDNA microarray

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001influential reference
• Minimum information about a microarray experiment (MIAME)—toward standards for microarray data

  2001cited by this paper
• High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8.

  1998cited by this paper
• The National Comprehensive Cancer Network

  1998cited by this paper
• Molecular cloning of a human neuroD from a neuroblastoma cell line specifically expressed in the fetal brain and adult cerebellum.

  1996cited by this paper
• The human FGF-8 gene localizes on chromosome 10q24 and is subjected to induction by androgen in breast cancer cells.

  1996cited by this paper
• Cancer Therapy: Prognostic Factors and Criteria of Response

  1976cited by this paper

• p53 inactivation drives breast cancer metastasis to the brain through SCD1 upregulation and increased fatty acid metabolism

  2025cites this paper
• Improved outcomes for triple negative breast cancer brain metastases patients after stereotactic radiosurgery and new systemic approaches

  2024cites this paper
• Inactivation of p53 drives breast cancer brain metastasis by altering fatty acid metabolism

  2023cites this paper
• SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

  2022cites this paper
• Understanding Patterns of Brain Metastasis in Triple-Negative Breast Cancer and Exploring Potential Therapeutic Targets

  2021cites this paper
• OTT_A_293685 589..607

  2021cites this paper
• “Triple-Negative Breast Cancer Central Nervous System Metastases From the Laboratory to the Clinic”

  2021cites this paper
• HER2 receptor conversion is a strong survival predictor in patients with breast cancer brain metastases.

  2021cites this paper
• Brain Metastases Surgical Management: Diagnostic, Therapeutic and Strategic Considerations

  2020cites this paper
• Central Nervous System Metastases

  2020influential citation
• Bioinformatics analysis of the genes involved in the extension of proCriteriastate cancer to adjacent lymph nodes by supervised and unsupervised machine learning methods: The role of SPAG1 and PLEKHF2.

  2020cites this paper
• Genomic landscape of the immune microenvironments of brain metastases in breast cancer

  2020cites this paper
• Surgery in Brain Metastasis Management: Therapeutic, Diagnostic, and Strategic Considerations

  2019cites this paper
• A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases

  2019cites this paper
• Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer

  2018cites this paper
• Breast cancer brain metastasis: molecular mechanisms and directions for treatment.

  2018cites this paper
• Genomic Profiling of Brain Metastasis and Matched Primary Triple-negative Breast Cancer.

  2017cites this paper
• Comprehensive molecular biomarker identification in breast cancer brain metastases

  2017cites this paper